Scilex Holding CO 8-K filings

Scilex Holding Company reported preliminary unaudited financial results for the quarter ended September 30, 2024, indicating revenue growth for both ZTlido and total product net sales compared to the same period last year.

Scilex Holding Company has finalized a $50 million registered convertible financing to refinance existing debt and strengthen its financial position.

Scilex Holding Company has obtained an extension on a $2 million payment to Oramed Pharmaceuticals, now due October 8, 2024, to allow time to close a convertible debt financing.

Scilex Holding Company has reached an agreement with Oramed Pharmaceuticals to amend their existing debt and warrant agreement, providing immediate debt relief and warrant repurchase.

Scilex Holding Company has entered into an agreement to satisfy a $10 million loan obligation by delivering 28,000 cartons of ZTlido product, while also securing ongoing distribution support from Endeavor Distribution LLC.

Semnur Pharmaceuticals, a Scilex subsidiary, has agreed to a merger with Denali Capital Acquisition Corp., valuing Semnur at $2.5 billion, to create a publicly traded biopharma company focused on non-opioid pain therapies.

Scilex Holding Company announced preliminary unaudited net sales for July 2024, showing significant growth compared to the same period last year.

Scilex Holding Company has appointed Dr. Annu Navani, a leader in interventional and multidisciplinary spine care, to its Board of Directors.

Scilex Holding Company has received a $2.5 million settlement payment from Virpax Pharmaceuticals, resolving part of a legal dispute.

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, has signed a letter of intent for a business combination with Denali Capital Acquisition Corp., valuing Semnur at up to $2 billion.

Scilex Holding Company reported preliminary unaudited financial results for Q2 2024, highlighting significant year-over-year sales growth for ZTlido and total products, alongside reduced operating expenses and net loss.

Scilex Holding Company's board has authorized exploring options to maximize the value of its subsidiary Semnur, including a potential dividend of up to 10% of its ownership interest.

Scilex Holding Company received a $10 million deposit and used it to pay off the remaining $10.4 million owed to Oramed Pharmaceuticals.

Scilex Holding Co.'s board has authorized management to explore strategic options to maximize the value of its subsidiary, Semnur Pharmaceuticals, and its product candidate, SP-102.

Scilex Holding Company has entered into a commitment letter for a $100 million loan, including the issuance of warrants to purchase common stock.

Scilex Holding Company has sent letters to the U.S. Securities and Exchange Commission and the Financial Industry Regulatory Authority regarding alleged illegal market manipulation of its common stock.

Scilex Holding Company has sent a letter to the U.S. House of Representatives alleging illegal market manipulation of its common stock.

Scilex Holding Company is taking action against what it believes is manipulative and naked short selling of its common stock, which it believes is negatively impacting shareholder value.

Scilex Holding Company has successfully completed a registered direct offering, raising $15 million through the sale of common stock and warrants.

Scilex Holding Company reported preliminary unaudited first-quarter 2024 results showing growth in ZTlido sales and announced plans to reduce R&D and administrative expenses.

Scilex Holding Company held its 2024 Annual Meeting of Stockholders, electing two Class II directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.

Scilex Holding Company announced that the U.S. Bankruptcy Court has extended the lock-up period for shares previously distributed by Sorrento Therapeutics as a dividend.

Scilex Holding Company and Yorkville have mutually agreed to terminate their $500 million Standby Equity Purchase Agreement, effective March 25, 2024.

Scilex Holding Company has reached a settlement with Takeda Pharmaceuticals, resolving a patent infringement lawsuit related to Scilex's application to expand the label for its gout medication, Gloperba.

Scilex Holding Company successfully closed a public offering, raising $10 million to support working capital and general corporate purposes.

Scilex Holding Company has entered into an agreement to sell 5,882,353 shares of common stock and accompanying warrants at $1.70 per share, aiming to raise approximately $10 million.

Scilex Holding Company has reached a settlement agreement with Virpax Pharmaceuticals, resolving a legal dispute and securing $6 million in payments plus potential royalties.

Scilex Holding Company and B. Riley Principal Capital II, LLC have mutually agreed to terminate their Standby Equity Purchase Agreement, effective February 16, 2024.

Scilex Holding Company's subsidiary, Scilex Pharmaceuticals, has settled a lawsuit against two manufacturers of over-the-counter lidocaine patch products.